

# Drug response prediction by inferring pathway-response associations with Kernelized Bayesian Matrix Factorization

Muhammad Ammad-ud-din<sup>\*1</sup>, Suleiman A.Khan<sup>2</sup>, Disha  
Malani<sup>2</sup>, Astrid Murumägi<sup>2</sup>, Olli Kallioniemi<sup>2,3,4</sup>, Tero  
Aittokallio<sup>2,5</sup>, and Samuel Kaski<sup>†1</sup>

<sup>1</sup>Helsinki Institute for Information Technology HIIT, Department  
of Computer Science, Aalto University, 02150 Espoo, Finland.

<sup>2</sup>Institute for Molecular Medicine Finland FIMM, University of  
Helsinki, 00290 Helsinki, Finland.

<sup>3</sup>Science for Life Laboratory,

<sup>4</sup>Department of Oncology and Pathology, Karolinska Institutet,  
17165 Solna, Sweden.

<sup>5</sup>Department of Mathematics and Statistics, University of Turku,  
20014 Turku, Finland.

March 8, 2022

## Abstract

A key goal of computational personalized medicine is to systematically utilize genomic and other molecular features of samples to predict drug responses for a previously unseen sample. Such predictions are valuable for developing hypotheses for selecting therapies tailored for individual patients. This is especially valuable in oncology, where molecular and genetic heterogeneity of the cells has a major impact

---

<sup>\*</sup>muhammad.ammad-ud-din@aalto.fi

<sup>†</sup>samuel.kaski@aalto.fi

on the response. However, the prediction task is extremely challenging, raising the need for methods that can effectively model and predict drug responses. In this study, we propose a novel formulation of multi-task matrix factorization that allows selective data integration for predicting drug responses. To solve the modeling task, we extend the state-of-the-art kernelized Bayesian matrix factorization (KBMF) method with component-wise multiple kernel learning. In addition, our approach exploits the known pathway information in a novel and biologically meaningful fashion to learn the drug response associations. Our method quantitatively outperforms the state of the art on predicting drug responses in two publicly available cancer data sets as well as on a synthetic data set. In addition, we validated our model predictions with lab experiments using an in-house cancer cell line panel. We finally show the practical applicability of the proposed method by utilizing prior knowledge to infer pathway-drug response associations, opening up the opportunity for elucidating drug action mechanisms. We demonstrate that pathway-response associations can be learned by the proposed model for the well known EGFR and MEK inhibitors.

## 1 Introduction

The fundamental aim of personalized medicine is to design and identify individualized therapies that maximize drug efficacy while minimizing the undesirable side effects. The efficacy, however, depends on a multitude of factors, including molecular, genetic, environmental and clinical characteristics of the samples, and much of this information remains unknown. A promising research direction is to computationally learn to predict, based on the available molecular and genetic descriptions of the samples, the responses they elicit in lab when exposed to a spectrum of drugs. The learned predictors help identifying potential drug response associations, and can predict responses for a new sample.

The development of molecular and genetic models of drug response has been made possible through several recent large scale high-throughput screening efforts that profile large panels of human cancer cell lines and drugs (Barretina et al., 2012; Garnett et al., 2012; Basu et al., 2013). Such models open up the opportunity to study the impact of molecular characteristics on the response, increasing our understanding of cancer vulnerabilities as well as making it possible to build predictive models of drug responsiveness.

Recent advances have demonstrated that molecular and genomic features have been useful in predicting the drug responses in cell lines (Costello et al., 2014; Jang et al., 2014). However, a key challenge underlying predictive mod-

eling is the small sample size and very large number of genomic features. The small sample sizes offer limited statistical power leading to high uncertainty in the predictions. The inherent heterogeneity across and within different cancer types makes robust inference even harder. In the absence of technical and practical facilities to overcome these limitations, a prospective direction is to incorporate additional prior knowledge in a biologically meaningful way to facilitate the learning process.

From the computational perspective, several methodologies have been used to predict drug response (a detailed discussion in Section 2). A key constituent of inferring the molecular and genetic model is the ability to effectively integrate multiple side-data views (also called as side-data sources) for prediction of the drug responses. Methods commonly referred to as multiple kernel learning MKL (Gönen and Alpaydm, 2011) can extract the common signal from multiple side-data views, effectively yielding an increased signal-to-noise ratio in the parameter space and are currently the state of the art in drug response prediction (Costello et al., 2014). Multi-task learning makes it possible to learn a predictive model for all of the drugs jointly (multi-task) making it possible to gather statistical evidence across multiple drugs (Baxter, 2000).

In this study we introduce component-wise multiple kernel learning (MKL) into the recent kernelized Bayesian matrix factorization (KBMF) method (Gönen et al., 2013). The proposed model solves the prediction task by gathering evidence from multiple side-data views, selectively, for each of the output variable group. This formulation is particularly useful in drug response prediction, for taking into account multiple side-data views. It need not assume the same views to be relevant to all drugs as earlier methods, but instead predictions can be based on different views for different groups of drugs. The multiple side-data views can be generated based on the prior biological knowledge; in the paper we use the pathways that are linked to the known primary targets of the drugs. By systematically utilizing this type of prior knowledge through kernelized Bayesian matrix factorization with the component-wise MKL approach, we hypothesize that pathway-drug response associations can be learned which are more informative for response prediction, and additionally are better interpretable for understanding drug action mechanisms.

## Contributions

In this paper, we present a novel approach for improving accuracy of predicting drug responses and elucidating the underlying pathway-drug response associations. Specifically, our contributions are two-fold:

1. Methodologically we extend the current state-of-the-art model kernelized Bayesian matrix factorization (KBMF) with component-wise multiple kernel learning (MKL). The extension can be seen as multi-task learning by task factorization, however with selective data integration. Here the key assumption is that component-wise MKL allows the method to better use prior biological knowledge (pathways) input as multiple side-data views.
2. We introduce a way for incorporating prior biological knowledge, in the form of pathways, for modeling pathway-drug response associations. Instead of using a single side-data view for the genomic features, we present pathway-based groups of features as multiple side-data views. Here the key assumption is that informed grouping of the features introduces additional structure and knowledge that is valuable for prediction of particular drug groups.

We first demonstrate the model’s predictive abilities on a synthetic data set. We then substantiate the significantly better performance of our approach on predicting drug responses in two large publicly available cancer data sets. In addition, we validate the *in silico* predictions of our model with lab experiments on an in-house Acute Myeloid Leukemia (AML) cell line panel. Finally, we examine the inferred associations between drug responses and pathways in the larger data set, demonstrating a mechanism for elucidating drug action mechanisms.

## 2 Related Work in drug response prediction

The computational task underlying personalized medicine is to predict drug responses on new cancer cell lines, given a set of cancer cell lines for which some measurements of drug responses are observed.

A common approach is to use the mean of the observed responses as predictions for the unobserved (unseen) drug responses (used as baseline method here). Another well-known supervised approach uses the genomic and molecular features of the cell lines (as input side-data) and the observed drug responses to learn a predictive model of the drug responses (Jang et al., 2014). The available molecular and genomic features range from gene expression to copy number and point mutations for the cancer cell lines, respectively (Barretina et al., 2012; Garnett et al., 2012).

Another widely used approach is the quantitative structure-activity relationship (*QSAR*) analysis which uses chemical and structural properties (often called as descriptors) of the drugs and the observed responses to learn

a predictive model to infer the unobserved responses. The descriptors vary from 2D fingerprints to spatial characteristics and physiochemical features of the drugs (Perkins et al., 2003; Myint and Xie, 2010; Shao et al., 2013). Recently, an advanced approach has been proposed that learns a joint predictive model of the observed drug responses by combining both the genomic features of the cell lines and descriptors of the drugs (Menden et al., 2013; Ammad-ud din et al., 2014; Cortés-Ciriano et al., 2015; Zhang et al., 2015; Cichonska et al., 2015).

Previous studies have used linear as well as non-linear methods. Linear methods including multivariate linear regression, partial least squares (PLS) and principal component regression (PCR) are the most prominent. Sparse linear regression has been well studied for identifying potential features predictive of drug responses by enforcing elastic net regularization techniques (Garrett et al., 2012; Barretina et al., 2012; Chen et al., 2015).

Nonlinear drug response analysis including kernel method, neural networks and random forests have also been studied (Sutherland et al., 2004; Yamanishi et al., 2012; Menden et al., 2013; Cortés-Ciriano et al., 2015; Zhang et al., 2015; Cichonska et al., 2015).

In particular, Costello et al. (2014) proposed Bayesian multi-task multiple kernel learning (BMTMKL) to predict drug responses on new human breast cancer cell lines. The BMTMKL method uses a kernelized regression approach that combines multi-task and multi-view learning (i.e., learning from multiple side-data views) with Bayesian inference to estimate the model parameters. Their results showed that modeling nonlinearities in the data was an essential attribute to predict drug responses. However, the model makes the simplifying assumption that the predictions are based on a single underlying component.

Alternatively, matrix factorization models integrating side-data views have also been studied in drug response analysis. The main idea behind these methods is to jointly factorize the side-data views and output matrix to finding a better low-dimensional latent representation (components) for both rows and columns of the output matrix. To this end, Zhou et al. (2012) proposed kernelized probabilistic matrix factorization (KPMF), a low-rank matrix factorization method that uses Gaussian process priors with covariance matrix on side-data view. While the method can explain tasks with multiple components, it is, however, limited to a single kernel for each side and, therefore, is unable to learn from multiple side-data views.

Recently, a kernelized Bayesian matrix factorization (KBMF) extending kernelized matrix factorization with fully Bayesian inference, combining multiple side-data views to jointly factorize the output matrix has been proposed (Gönen et al., 2013; Gönen and Kaski, 2014). With side-data views

encoded as kernel functions, the main idea is to project each kernel onto a low-dimensional component space, where they are combined with the kernel weights to get a composite component space of the output matrix. The KBMF method has been studied in various applications ranging from drug-target to drug response predictions (Gönen, 2012; Ammad-ud din et al., 2014). However, KBMF integrates multiple side-data views assuming that a source is either relevant for all tasks or none, failing to identify component-specific dependencies between the side-data views and the output matrix.

### 3 Methods

#### Kernelized Bayesian Matrix Factorization (*cw*KBMF)

We introduce a novel extension of the state-of-the-art kernelized Bayesian matrix factorization method to model the complex associations between a large number of side-data views and the latent component space of the output matrix. This new formulation of kernelized Bayesian matrix factorization (KBMF) allows component-wise multiple kernel learning (MKL), referred to as *cw*KBMF for brevity. *cw*KBMF is characterized by the ability to comprehensively model the associations that allow two advancements: i) improve the predictive power of the model; and ii) identify the component-specific latent dependencies for interpreting the associations.

The model is defined for the factorization of a given matrix  $\mathbf{Y} \in \mathbb{R}^{N_x \times N_z}$ , using known sets of  $P_x$  side-data views for the rows and  $P_z$  side-data views for the columns. In order to represent non-linear associations, similarities between samples in the side-data views are encoded as input kernel matrices  $\{\mathbf{K}_{x,m} \in \mathbb{R}^{N_x \times N_x}\}_{m=1}^{P_x}$  and  $\{\mathbf{K}_{z,n} \in \mathbb{R}^{N_z \times N_z}\}_{n=1}^{P_z}$ . Here matrices are denoted by capital letters, with the subscript ( $x$  or  $z$ ) indicating the corresponding side of the model. All equations are formulated, however, with corresponding scalar entities denoted by non-capital letters, with the superscript denoting the row index and the last subscript representing the column index (i.e.,  $a_{x,s}^i$  denotes the entry at (row  $i$ , column  $s$ ) of matrix  $\mathbf{A}_x$ ). Without compromising the generalizability, the rest of this article focuses on multiple side-data views in the rows only.

The model is specified as a low-rank factorization of the matrix  $\mathbf{Y}$  such that the latent representations  $\mathbf{H}_x \in \mathbb{R}^{N_x \times R}$  and  $\mathbf{H}_z \in \mathbb{R}^{N_z \times R}$  are learned jointly from  $\mathbf{Y}$  and the  $\mathbf{K}_{x,m}$ ,  $\mathbf{K}_{z,n}$  side-data views. This is achieved by an interplay of two elements. First, each of the  $\{\mathbf{K}_{x,m}\}_{m=1}^{P_x}$  kernels is transformed to a lower dimensional sub-space  $\{\mathbf{G}_{x,m} \in \mathbb{R}^{N_x \times R}\}_{m=1}^{P_x}$  through a common projection matrix  $\mathbf{A}_x \in \mathbb{R}^{N_x \times R}$ . The low-rank transformations of the kernels

are combined using multiple kernel learning to compute the latent matrix factors  $\mathbf{H}_x$ .

The *cwKBMF* method is formulated in a Bayesian setting using conjugate priors, where  $\mathcal{N}(\cdot; \mu, \Sigma)$  denotes the normal distribution with mean  $\mu$  and covariance  $\Sigma$ , while  $\mathcal{G}(\cdot; \alpha, \beta)$  is the gamma distribution with the parameters, shape  $\alpha$  and scale  $\beta$ . The matrix factorization is formulated as

$$y_j^i | h_{\mathbf{x},i}, h_{\mathbf{z},j} \sim \mathcal{N}(y_j^i; h_{\mathbf{x},i}^\top h_{\mathbf{z},j}, \sigma_y^2) \quad \forall(i, j)$$

where  $i = 1 : N_x$  and  $j = 1 : N_z$  denote the samples and  $\sigma_y$  the noise. Here  $h_{\mathbf{x},i}$  and  $h_{\mathbf{z},j}$  are vectors of length  $R$ , the number of components, and represent the low-dimensional factors of the samples in  $Y$ .

Our extension formulates this factorization with the novel component-wise MKL and has the distributional assumptions:

$$\begin{aligned} \eta_{\mathbf{x},m}^s &\sim \mathcal{G}(\eta_{\mathbf{x},m}^s; \alpha_\eta, \beta_\eta) & \forall(m, s) \\ e_{\mathbf{x},m}^s | \eta_{\mathbf{x},m}^s &\sim \mathcal{N}(e_{\mathbf{x},m}^s; 0, (\eta_{\mathbf{x},m}^s)^{-1}) & \forall(m, s) \\ h_{\mathbf{x},i}^s | \{e_{\mathbf{x},m}^s, g_{\mathbf{x},m,i}^s\}_{m=1}^{P_x} &\sim \mathcal{N}\left(h_{\mathbf{x},i}^s; \sum_{m=1}^{P_x} e_{\mathbf{x},m}^s g_{\mathbf{x},m,i}^s, \sigma_h^2\right) & \forall(s, i) \end{aligned}$$

where superscript  $s = 1 : R$  denotes the components. The novel advancement of this formulation is in learning the latent components  $\mathbf{H}_x$  as a combination of kernel-specific components  $\{\mathbf{G}_{\mathbf{x},m} \in \mathbb{R}^{N_x \times R}\}_{m=1}^{P_x}$  while segregating between kernels that are component-specific and those which are shared across all components. This is achieved by introducing component-specific kernel weights  $\mathbf{e}_{\mathbf{x},m}^s \in \mathbb{R}^{P_x \times R}$  that control the activity of each kernel in each component. This extension makes it possible for the method to effectively learn the underlying structure for identifying the associations between kernels and components. The method can also be viewed as combination of component-wise multiple kernel learning and matrix factorization. The  $\eta_{\mathbf{x},m}^s$  defines an element-wise prior for the kernel-weights  $e_{\mathbf{x},m}^s$ , making it possible to effectively switch off some of the weights in a component-wise fashion.

Finally, the dimensionality reduction of the model has the distributional assumptions:

$$\begin{aligned} \lambda_{\mathbf{x},s}^i &\sim \mathcal{G}(\lambda_{\mathbf{x},s}^i; \alpha_\lambda, \beta_\lambda) & \forall(i, s) \\ a_{\mathbf{x},s}^i | \lambda_{\mathbf{x},s}^i &\sim \mathcal{N}(a_{\mathbf{x},s}^i; 0, (\lambda_{\mathbf{x},s}^i)^{-1}) & \forall(i, s) \\ g_{\mathbf{x},m,i}^s | a_{\mathbf{x},s}, k_{\mathbf{x},m,i} &\sim \mathcal{N}(g_{\mathbf{x},m,i}^s; a_{\mathbf{x},s}^\top k_{\mathbf{x},m,i}, \sigma_g^2) & \forall(m, s, i) \end{aligned}$$

where a joint  $A_x$  matrix projects each of the kernels to a low-dimensional representation. The hyper-parameters  $\alpha_\lambda, \beta_\lambda, \alpha_\eta, \beta_\eta, \sigma_g, \sigma_h, \sigma_y$  can be used

to express prior knowledge about the data-generating process, or set to uninformative values (as in this paper).

The model is formulated with conjugate priors and variational approximation is used to perform model inference. The computational complexity of the model is  $\mathcal{O}(R \max(N_x^3, N_z^3) + R \max(P_x^3, P_z^3))$  which is faster than standard pair-wise kernel approaches (Ben-Hur and Noble, 2005) and slower only linearly with a factor of  $R$  in  $\max(P_x^3, P_z^3)$ , in comparison to original KBMF formulation. The model achieves a run time to the tune of minutes for reasonably sized data sets ( $\approx 5$  minutes of wall clock time on a standard computer, for a single cross validation fold on the largest data studied in this manuscript).

## Publicly Available Data sets and Preprocessing

We used two publicly available cancer data sets to model drug response associations in this study.

**Genomics of Drug Sensitivity in Cancer:** The first data come from Genomics of Drug Sensitivity in Cancer (GDSC) project initiated by Wellcome Trust Sanger Institute version release, June 2014 (Yang et al., 2013). The data comprised of 124 human cancer cell lines and 124 anti-cancer drugs, for which complete drug response measurements are available and the response range is consistent with earlier publications (Garnett et al., 2012; Menden et al., 2013). Drug response measurements are summarized as  $\log IC_{50}$  values (micro molar concentration of a drug required to inhibit 50% of the cell growth) obtained by curve fitting through the 9-point dose response data. The cell lines are annotated with tissue type, and drugs with their primary therapeutic targets.

**Cancer Therapeutic Response Portal:** The second data originate from Cancer Therapeutic Response Portal (CTRP) version release v1 2013, (Basu et al., 2013) by Broad Institute summarizing area-under-concentration-response curve (AUC) values from 8-point dose response data measured on human cancer cell lines. For our case study, we focus on the set of 66 cell lines and 63 anti-cancer drugs, whose AUC values were observed without missing values. The molecular profiles for the cell lines was obtained from Cancer Cell line Encyclopedia CCLE (Barretina et al., 2012). As in GDSC, the cell lines are annotated with tissue type and gene expression, while drugs with their primary therapeutic targets.

As the input data, we used the baseline gene expression values of all the



cell lines quantizing the number of transcripts expressed in a cell. These measurements characterize the genome-wide molecular profiles that may be indicative of the response patterns.

**Prior Biological Knowledge:** In order to incorporate prior biological knowledge, we used a selected set of pathways and gene sets from Molecular Signature database MSigDB (Liberzon et al., 2011). Specifically, we extracted the C2CP and C6 collections of pathways and genesets from MSigDB, respectively. C2CP contains pathways compiled from online pathway databases, biomedical literature, published mammalian gene expression studies and MYC target gene database. C6 gene sets denote oncogene signatures of cellular pathways which are often dis-regulated in cancer. These oncogene signatures are computed using microarray data from NCBI GEO and from profiling experiments involving perturbation of known cancer genes. For simplicity in the rest of the paper, we use a common term for both of the collections: *pathways*.

## Experimental Setup

**Incorporating Prior Biological Knowledge:** We focused the analyses on drug targets by, for each of the two collections, carefully selecting the subset of pathways that were directly linked to the known primary targets of the drugs. This was done by examining the correspondence between pathway names and the known primary targets of the drugs. The drug target data coming from the original annotations of GDSC and CTRP was used for this purpose. The gene expression data were then split into groups of genes, where each group represented one pathway. All the other genes which were not part of any of the target-based pathway selection, were collected in a separate single group (collectively called as “*other genes*”). When the variable groups in the data are constructed in this way, the component-wise MKL based data integration can choose what prior knowledge is useful for predicting responses. Still, no knowledge is lost as all variables have been included, and additionally allows to learn associations between other genes and the responses. The total number of groups formed per case study are listed in Table 1. We term each group with a keyword ‘*view*’.

Table 1: Data used in the drug response predictions.

Datasets	Cells	Drugs	Genes	Primary Targets	Views
GDSC	124	124	13321	60	72 (71 pathways, 1 other genes)
CTRP	66	63	18988	58	26 (25 pathways, 1 other genes)

Additional information about the data including the names of the cell lines, drugs, primary targets and pathways can be found from the supplementary material. The response data consist of both types of drugs: FDA approved ‘drugs’ and ‘investigational chemical compounds’. In the paper, we use both of these terms interchangeably.

**Cross-Validation:** We compared the performance of *cuKBMF* with several methods including  $\text{KBMF}_{\text{multi-view}}$ ; kernelized Bayesian matrix factorization with pathway based groups,  $\text{BMTMKL}_{\text{multi-view}}$ ; Bayesian multi-task learning with pathway based groups,  $\text{KPMF}_{\text{single-view}}$ ; kernelized probabilistic matrix factorization without pathway based groups,  $\text{MT-LR}_{\text{single-view}}$ ; multi-task sparse linear regression without pathway based groups and the classical Baseline; mean of the training drug response data (assuming no genomic data is available).

We performed a 5-fold cross validation procedure, where in each fold a randomly selected subset of cell lines is completely held-out (as test cell lines) and models were trained on the remaining cell lines (training data). To establish robust findings the 5-fold cross validation procedure was repeated 10 times with different random cross-validation folds.

For the kernelized Bayesian methods ( $\text{BMTMKL}$ ,  $\text{KBMF}$  and *cuKBMF*), we use uninformative priors for the projection matrices and the kernel weights. In particular, the hyperparameter values for  $\text{BMTMKL}$  are selected as  $(\alpha_\lambda, \beta_\lambda, \alpha_v, \beta_v, \alpha_\gamma, \beta_\gamma, \alpha_\omega, \beta_\omega, \alpha_\epsilon, \beta_\epsilon) = (1, 1, 1, 1, 1, 1, 1, 1, 1, 1)$  and for  $\text{KBMF}$ , *cuKBMF* are selected as  $(\alpha_\eta, \beta_\eta, \alpha_\lambda, \beta_\lambda) = (1, 1, 1, 1)$ , and the standard deviations  $(\sigma_g, \sigma_h, \sigma_y)$  are set to  $(0.1, 0.1, 1)$ . For  $\text{KPMF}$ , the standard deviation  $\sigma_y$  is set to one. For the side-data views, we computed Gaussian kernels, where the width parameter  $\sigma$  was set in the standard way ( $\sigma = \text{dimensionality of the side-data view}$ ). The drug response measurements were normalized to have zero mean and unit variance.

We used multi-task sparse linear regression using the *glmnet* package (Friedman et al., 2010). The sparse linear regression has two parameters that are to be optimized:  $\alpha$  (elastic net mixing parameter) and  $\lambda$  (the penalty parameter). For each test set prediction, we performed a nested 5-fold cross validation procedure on the training data, to choose optimal values for  $\alpha \in [0, 1]$  with an increment of 0.1 and  $\lambda$  (from 100 values). We finally selected a combination of  $\alpha$  and  $\lambda$  values that gave minimum error averaged over the cross-validated folds.

**Evaluation Criteria:** We evaluated the predictive performance of *cuKBMF* and other methods using drug-wise spearman correlation as an evaluation

criterion and report an averaged correlation for each drug from 10 random repeats of the cross-validation procedure. In addition, the correlations were averaged to obtain a cumulative correlation value for each method.

## 4 Results and Discussion

### Synthetic Data Set




Figure 1: Identification of component-view activities and predictions on synthetic data set. Method abbreviation: *cwKBMF*, kernelized Bayesian matrix factorization with component-wise MKL; *KBMF*, kernelized Bayesian matrix factorization. Left: The component-view activities learned by the model. Black indicates that a view is active in a component while white represents not-active. Middle: the mean squared error (MSE) of predictions, averaged over 100 data sets at each point (and bars denoting 1-standard error of the mean (1SE)). The performance is indicative of the models ability to discover the underlying structure of the data. Right: The accuracy of the model to discover component-view associations. The true and the inferred, averaged accuracy of the associations from 100 data sets are marked for shared, specific and empty component, along with 1SE. The figure demonstrates the models ability to accurately discover the component-view associations.

To demonstrate that the model can infer the true associations between multiple side-data views and components, we perform the first experiment using synthetic data set. Specifically, the *cwKBMF* method has been designed to learn the complex relationships patterns, by representing them as activity profiles of components over the views.

To this end, 100 synthetic data sets  $\mathbf{Y}$  with  $N_x = 100$ ,  $N_z = 100$  and  $R = 3$  components were generated such that each data set was supplemented with  $P_x = 10$  side-data views (encoded as kernels). The associations between the  $P_x = 10$  side-data views and  $K = 3$  components were encoded such that one

view is active in all the components (shared), while the rest are equally split into  $K+1$  sets, where each view is either active in one component (specific) or not active in any of the components (empty). Here the key assumption is that given the kernels for  $P_x = 10$  side-data views and the output matrix  $\mathbf{Y}$ , the model decomposes  $\mathbf{Y}$  into components while accurately learning the associations between kernels and components. In addition, 1% values in each  $\mathbf{Y}$  were marked as missing data (test set) to measure the predictive accuracy of the model.

The model is run for each of the 100 data sets to learn the associations. The component-view weights  $e_x^s$  represent the activity of each view  $x = 1 : P_x$  in components  $s = 1 : R$ . Since the model is encoded with an element-wise prior it can be effectively thresholded to illustrate component-view activity. In order to focus on the most important associations for each component, we consider the associations that are notably strong with respect to the prior (i.e., z-score ( $e_x^s$ )  $> 0.67$ ) as active. Figure 1 (left) shows the resulting component-view activities inferred by the model for  $P_x = 10$ . The figure demonstrates that the model is able to accurately discover the component-view activities as inserted in the data (described above), up to a random permutation of the components.

Next, we measured the accuracy of the model in inferring the component-view activities as well as in predicting unobserved values in  $Y$  over a range of side-data views  $P_x$ . The associations were learned and prediction performance was evaluated for 100 data sets for each value of  $P_x$ . Figure 1 (right panel) demonstrates the accuracy of learning the associations, particularly the model performs well in discovering the shared, specific as well as empty components over the range of input views. In addition, Figure 1 (middle panel), *cuKBMF* consistently outperforms *KBMF* in the prediction task as well, especially when the number of views is large. As expected, the performance of the methods deteriorates as the number of views (dimensionality) increases. However, *cuKBMF* performs reasonably well over the number of views applicable to the drug-response prediction data sets in this study.

## Cancer Data Sets

We next compare *cuKBMF* with alternatives on two case studies GDSC and CTRP, and report their predictive performance in the 5-fold cross validation procedure (described in Section 3). To evaluate the new model extension and the benefit of the principled incorporation of prior knowledge, we compare *cuKBMF*'s performance to other methods in two scenarios,

1. Genomic Data + Prior Knowledge: The genomic features are divided into several side-data views based on the prior knowledge about the




Figure 2: Prediction performances (Spearman correlation) averaged over drugs with a 5 fold cross-validation procedure repeated 10 times. GDSC data set (left) and CTRP data set (right). Method abbreviation: *cwKBMF*, kernelized Bayesian matrix factorization with component-wise MKL; *KBMF*, kernelized Bayesian matrix factorization; *BMTMKL*, Bayesian multi-task MKL; *KPMF*, kernelized probabilistic matrix factorization; *MT-LR*, multi-task sparse linear regression; *Baseline*, mean of the training data. The predictive performance obtained by *cwKBMF* for both scenarios is found to be significantly higher than the others ( $p < 0.05$ ; one-sided paired Wilcoxon Sign-Rank test corrected for multiple testing, supplementary material Tables S3 and S6).

pathways. We represent this scenario with a subscript *multi-view* in the results; and

2. Genomic Data (only): The genomic features are used as a single view and does not benefit from the prior knowledge. We denote this scenario with a subscript *single-view* in the results.

Figures 2 show the predictive performances of all the methods on the GDSC (left) and CTRP (right) data sets. *cwKBMF* outperforms its competitors for both scenarios. Even though the differences in performances are rather small, the predictive performance obtained by *cwKBMF* for both scenarios is found to be significantly higher than the others ( $p < 0.05$ ; one-sided paired Wilcoxon Sign-Rank test corrected for multiple testing, supplementary material Table S3) in GDSC data set respectively. Similarly in CTRP data set, the predictive performance obtained by *cwKBMF* for both scenarios is also significantly higher than the others ( $p < 0.05$ ; one-sided paired Wilcoxon Sign-Rank test, corrected for multiple testing, supplementary material Table S6). In the GDSC and CTRP data sets, the maximum predictive performance of *cwKBMF* is achieved with 10 and 20 components, respectively. However,

in-case of multiple maxima a practical choice could be to prefer solutions with smallest- $R$  in the interest of simpler representations. We chose these components and discuss a detailed comparison of the predictions of *cwKBMF* with other methods.

In GDSC data set, *cwKBMF*<sub>single-view</sub> outperforms Baseline, MT-LR<sub>single-view</sub> and KPMF<sub>single-view</sub> ( $p < 0.05$ ; one sided paired Wilcoxon Sign-Rank test, for comparing Spearman correlations). *cwKBMF*<sub>multi-view</sub> outperforms KBMF<sub>multi-view</sub> and Baseline methods ( $p < 0.05$ ; one-sided paired Wilcoxon Sign-Rank test, supplementary material Figure S1). Although *cwKBMF*<sub>multi-view</sub> performance is better than BMTMKL<sub>multi-view</sub> (averaged Spearman correlations 0.2253 and 0.2167, respectively), the difference is not statistically significant ( $p = 0.11$ ; one-sided paired Wilcoxon Sign-Rank test).

Similarly, in CTRP data set, *cwKBMF*<sub>single-view</sub> outperforms Baseline and MT-LR<sub>single-view</sub> ( $p < 0.05$ ; one-sided paired Wilcoxon Sign-Rank test). Although *cwKBMF*<sub>single-view</sub> performance is better than KPMF<sub>single-view</sub> (averaged Spearman correlation 0.1776 and 0.1673, respectively), the difference is not statistically significant ( $p = 0.07$ , one-sided paired Wilcoxon Sign-Rank test). *cwKBMF*<sub>multi-view</sub> give better predictions than Baseline, BMTMKL<sub>multi-view</sub> and KBMF<sub>multi-view</sub> ( $p < 0.05$ ; one-sided paired Wilcoxon Sign-Rank test, supplementary material Figure S3).

The prediction results generalize previous findings that non-linear models improve drug response predictions (Costello et al., 2014). Figure 2 clearly shows that non-linear methods are better than the linear counterpart, for predicting drug responses in both data sets.

Having established that our model outperforms existing methods in both single-view and multi-view settings, we next specifically study the advantage of using prior pathway and target knowledge. To this end, Figure 3 illustrates the improvement in performance (in % units) relative to Baseline and when genomic data is supplemented with prior knowledge.

As the first observation, the introduction of genomic data via different methods outperforms the baseline predictions demonstrating the genomic features are response predictive. Secondly, incorporating prior biological knowledge improves the prediction performance systematically over a range of methods. Third, systematically modelling the associations between pathway-based genomic profiles and drug response with *cwKBMF* outperforms the existing approaches in predicting drug responses. Specifically, in case of the GDSC data set, using genomic data with *cwKBMF* improves the prediction performance by 21% and when the genomic data is supplemented with prior knowledge the performance is improved by 22%. Similarly, in case of the CTRP dataset, using genomic data with *cwKBMF* improves the prediction




Figure 3: Pathway-based groups of genes (prior biological knowledge) improves predictive performance. Left, GDSC data set and Right, CTRP data set. The height of the bar (y-axis) denotes the percentage increase in performance relative to Baseline, computed using the Spearman correlations averaged over drugs. On x-axis, the bars are grouped based on the type of learning data used, where “ Genomic Data” means that all of the genes are used as one group and “Genomic Data + Prior Knowledge” means that all of the genes are used, grouped into several sets based on the pathway knowledge and lastly “No Genomic Data” implies that only mean of the training drug response data is used for prediction.

performance by 17% and when the genomic data is supplemented with prior knowledge the performance is improved by 20%. The findings also suggest that incorporating the prior knowledge is more beneficial when the number of samples is smaller (for instance, in the CTRP data set).

**Fully Blinded Experimental Validations:** Finally, we experimentally validated the drug response predictions of our model using an in-house Acute Myeloid Leukemia (AML) cell line panel (Malani et al., manuscript in preparation). The model is learned, analogously to the experiments with public data sets above, using the available training drug response data. Specifically, we made drug response predictions for 8 compounds using 6 AML cell lines of which 83% measurements were not available for initial model training. To validate the predictions, an independent experiment was carried out in laboratory. The predicted drug responses were found to be correlated with the independent lab measurements (Spearman correlation 0.44 Figure 4,  $p < 0.05$ ; compared to the distribution of correlation values obtained via randomization; supplementary material Figure S4). This fully-blinded experimental validation confirms the predictive power of the model, and gives confidence that *in silico* predictions are fairly robust and may be used to study the




Figure 4: Prediction of the drug sensitivity score (DSS; (Yadav et al., 2014)) of 8 compounds in 6 AML cell lines. The y-axis shows the predictions made by the *cv*KBMF model and the x-axis the corresponding validations as measured in the lab. The predictions have a spearman correlation of 0.44, and the correlation increases to 0.70, if the outlier venetoclax is excluded.

spectrum of therapeutic choices.

## Inferring Pathway-Drug Response Associations

The use of prior knowledge not only improves the prediction performance, but also helps to infer pathway-drug response associations by *cv*KBMF, being the first kernelized method making it possible to study such associations. We next study the pathway-drug response associations in the GDSC dataset.

We selected the model learned with 10 components based on cross-validation (as discussed in section 4) and show the pathway-drug response associations in Figure 5. A component can be characterized by the set of pathways that are active in it and the drugs whose responses they are predictive off, yielding hypotheses of pathways associated with drug responses. The hypotheses generated by all the ten components are illustrated in Figure 5, while those from the first two components are elaborated in detail below. In order to analyse target-driven effects, the components were sorted based on the consistency of the drug targets in the components.

**Component 1** is characterized by EGFR/ERBB2 inhibitors, lapatinib, erlotinib, BIBW2992 (afatinib) and gefitinib. On the pathway side, we



found *reactome SHC1 events in EGFR signalling*, *reactome GRB2 events in ERBB2 signaling*, among the top 10 pathways. It is biologically meaningful that the inhibitors are related to the EGFR signaling, making it possible to inhibit the pathways activity in cancer using the EGFR inhibitors. It is also evident that signaling pathways RAS-RAF-MAPK, PI3K/AKT and JAK/STAT mediate the downstream effect of EGFR autophosphorylation, thus affecting cellular proliferation, anti-apoptosis, metastasis and tumor invasion (Whirl-Carrillo et al., 2012). We give additional details of component 1 explaining the variation of EFGR responses in supplementary material Figure S2 (left). Other drugs explained by the component are aicar (target: AMPK agonist), thapsigargin (target: ATPase, Ca++ transporting, cardiac muscle, slow twitch 2), OSU-03012 (target: PDK1/PDPK1), GSK-650394 (target: SGK3), WZ-1-84 (target: BMX) and AZD-0530 (target: SRC, ABL1). The pathways involved in mediating the downstream signaling may generate novel hypotheses for the action mechanism of these drugs.

**Component 2** is representative of MEK inhibitors RDEA119 (refameetinib), PD-0325901, CI-1040 and AZD6244. Interestingly, on the pathway side, *MEK up..v1 up* is identified as one of the top pathways (shown in Figure 5). It is biologically plausible that the drugs are connected to the up-regulation of MEK pathway, making it possible to inhibit the pathway activity in cancer using the MEK inhibitors. It is also known that MEK inhibition leads to PI3K/AKT activation (Turke et al., 2012), supporting the identification of the AKT-related pathways in this component. In general, stimulation of the PI3K/AKT/mTOR cascade enhances growth, survival, and metabolism of many cancer cells, and therefore PI3K/AKT/mTOR signaling pathway is a promising therapeutic target for cancer therapy. We give additional details of component 2 explaining the variation of MEK responses in supplementary material Figure S2 (right). Other drugs explained by the component are bexarotene (target: Retinoic acid X family agonist), bicalutamide (target: Androgen receptor ANDR), MG-132 (target: Proteasome), TGX221 (target: PI3K beta), Salubrinal (target: GADD34-PP1C phosphatase) and FH535. In particular FH535 primary target is unknown, however it has been shown to downregulate the activity of Wnt/ $\beta$ -Catenin signaling pathway (Gedaly et al., 2014; Liu et al., 2014). The presence of FH535 in this component suggests potential associations between FH535 response, MEK and AKT-related pathways, which could be further investigated in the lab to identify novel biomarkers for predicting FH535 responses. The analysis conclude that pathway-drug response associations provide biologically meaningful findings. Even though these are well-known cancer-




Figure 5: Pathway-response associations decomposed into components in the GDSC data set, visualized as an “eye diagram” showing *cwKBMF* 10 components (circles), connecting pathways (right) and drugs (with their primary targets in parenthesis; left). The widths of the curves from the components to pathways and drugs indicate the strength of the corresponding associations. For each component, 10 drugs and 10 pathways showing the largest strength are shown.

related pathways (serving as proof-of-concept positive controls), the current clinical challenge is to find the patients in which these pathways are perturbed, making it possible to select targeted treatments like MEK inhibitors individually.

## 5 Conclusion

We extended the KBMF method with a novel approach of component-wise MKL. In experiments with two publicly available cancer data sets, the new method showed improved predictive performance compared to other methods (including its predecessor KBMF). Additionally, we confirmed the predictive performance of the method using an in-house AML cell line panel with experimental validation, performed independently in the lab. We also showed that incorporating prior knowledge in the form of pathways helps to improve the prediction performance. We also demonstrated the usefulness of component-wise MKL, combined with prior knowledge for inferring the associations between pathways and drug responses. This way of analyzing drug responses with groups of genes (encoded in the form of pathways) may enhance our understanding of the action mechanism of drugs and can potentially be used to identify novel predictive biomarkers for designing new therapies in cancer. In the future, the method could further be extended with strict sparsity assumptions for component-wise MKL, facilitating the discovery of potentially strong associations between pathways and drug responses.

## Acknowledgement

**Funding:** This work was financially supported by the Academy of Finland (Finnish Center of Excellence in Computational Inference Research COIN; grants 295503 and 292337 to MA and SK; grants 272437, 269862, 279163 to TA), and Cancer Society of Finland (TA). We acknowledge the computational resources provided by Aalto Science-IT project and CSC-IT Center for Science Ltd.

## Availability:

The source code implementing the method is available at <http://research.cs.aalto.fi/pml/software/cwkbmf/>.

# References

- Ammad-ud din, M., Georgii, E., Gönen, M., Laitinen, T., Kallioniemi, O., Wennerberg, K., Poso, A., and Kaski, S. (2014). Integrative and personalized QSAR analysis in cancer by kernelized Bayesian matrix factorization. *J. Chem. Inf. Model.*, 54(8):2347–2359.
- Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012). The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature*, 483(7391):603–607.
- Basu, A., Bodycombe, N. E., Cheah, J. H., Price, E. V., Liu, K., Schaefer, G. I., Ebright, R. Y., Stewart, M. L., Ito, D., Wang, S., et al. (2013). An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. *Cell*, 154(5):1151–1161.
- Baxter, J. (2000). A model of inductive bias learning. *J. Artif. Intell. Res.(JAIR)*, 12(149-198):3.
- Ben-Hur, A. and Noble, W. S. (2005). Kernel methods for predicting protein–protein interactions. *Bioinformatics*, 21(suppl 1):i38–i46.
- Benjamini, Y. and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society. Series B (Methodological)*, pages 289–300.
- Benjamini, Y. and Yekutieli, D. (2001). The control of the false discovery rate in multiple testing under dependency. *Annals of statistics*, pages 1165–1188.
- Chen, B.-J., Litvin, O., Ungar, L., and Pe’er, D. (2015). Context sensitive modeling of cancer drug sensitivity. *PloS one*, 10(8):e0133850.
- Cichonska, A., Rousu, J., and Aittokallio, T. (2015). Identification of drug candidates and repurposing opportunities through compound–target interaction networks. *Expert opinion on drug discovery*, 10:1–13.
- Cortés-Ciriano, I., van Westen, G. J., Bouvier, G., Nilges, M., Overington, J. P., Bender, A., and Malliavin, T. E. (2015). Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel. *Bioinformatics*, 31:btv529.
- Costello, J. C., Heiser, L. M., Georgii, E., Gönen, M., Menden, M. P., Wang, N. J., Bansal, M., Hintsanen, P., Khan, S. A., Mpindi, J.-P., et al. (2014). A community effort to assess and improve drug sensitivity prediction algorithms. *Nature biotechnology*, 32(12):1202–1212.
- Friedman, J., Hastie, T., and Tibshirani, R. (2010). Regularization paths for generalized linear models via coordinate descent. *Journal of statistical software*, 33(1):1.
- Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., Liu, Q., Iorio, F., Surdez, D., Chen, L., Milano, R. J., Bignell, G. R., Tam, A. T., Davies, H., Stevenson, J. A., Barthorpe, S., Lutz, S. R., Kogera, F., Lawrence, K., McLaren-Douglas, A., Mitropoulos, X., Mironenko, T., Thi, H., Richardson, L., Zhou, W., Jewitt, F., Zhang, T., O’Brien, P., Boisvert, J. L., Price, S., Hur, W., Yang, W., Deng, X., Butler, A., Choi, H. G., Chang, J. W., Baselga, J., Stamenkovic, I., Engelman, J. A., Sharma, S. V., Delattre, O., Saez-Rodriguez, J., Gray, N. S., Settleman, J., Futreal, P. A., Haber, D. A., Stratton, M. R., Ramaswamy, S., McDermott, U., and Benes, C. H. (2012). Systematic identification of genomic markers of drug sensitivity in cancer cells. *Nature*, 483(7391):570–575.
- Gedaly, R., Galuppo, R., Daily, M. F., Shah, M., Maynard, E., Chen, C., Zhang, X., Esser, K. A., Cohen, D. A., Evers, B. M., et al. (2014). Targeting the Wnt/ $\beta$ -catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with fh535. *PloS one*, 9(6):e99272.
- Gönen, M. (2012). Predicting drug–target interactions from chemical and genomic kernels using Bayesian matrix factorization. *Bioinformatics*, 28(18):2304–2310.
- Gönen, M. and Alpaydm, E. (2011). Multiple kernel learning algorithms. *The Journal of Machine Learning Research*, 12:2211–2268.
- Gönen, M. and Kaski, S. (2014). Kernelized Bayesian Matrix Factorization. *Pattern Analysis and Machine Intelligence, IEEE Transactions on*, 36(10):2047–2060.

- Gönen, M., Khan, S., and Kaski, S. (2013). Kernelized Bayesian Matrix Factorization. In *Proceedings of The 30th International Conference on Machine Learning*, pages 864–872.
- Jang, I. S., Neto, E. C., Guinney, J., Friend, S. H., and Margolin, A. A. (2014). Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data. In *Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing*, page 63. NIH Public Access.
- Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., and Mesirov, J. P. (2011). Molecular signatures database (msigdb) 3.0. *Bioinformatics*, 27(12):1739–1740.
- Liu, J., Li, G., Liu, D., and Liu, J. (2014). Fh535 inhibits the proliferation of hepg2 cells via downregulation of the Wnt/ $\beta$ -catenin signaling pathway. *Molecular medicine reports*, 9(4):1289–1292.
- Menden, M. P., Iorio, F., Garnett, M., McDermott, U., Benes, C., Ballester, P. J., and Saez-Rodriguez, J. (2013). Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. *PLoS One*, 8(4):e61318.
- Myint, K. Z. and Xie, X.-Q. (2010). Recent advances in fragment-based qsar and multi-dimensional qsar methods. *Int. J. Mol. Sci.*, 11(10):3846–3866.
- Perkins, R., Fang, H., Tong, W., and Welsh, W. J. (2003). Quantitative structure-activity relationship methods: Perspectives on drug discovery and toxicology. *Environ. Toxicol. Chem.*, 22(8):1666–1679.
- Shao, C.-Y., Chen, S.-Z., Su, B.-H., Tseng, Y. J., Esposito, E. X., and Hopfinger, A. J. (2013). Dependence of qsar models on the selection of trial descriptor sets: A demonstration using nanotoxicity endpoints of decorated nanotubes. *J. Chem. Inf. Model.*, 53(1):142–158.
- Sutherland, J. J., O’Brien, L. A., and Weaver, D. F. (2004). A comparison of methods for modeling quantitative structure-activity relationships. *J. Med. Chem.*, 47(22):5541–5554.
- Turke, A. B., Song, Y., Costa, C., Cook, R., Arteaga, C. L., Asara, J. M., and Engelman, J. A. (2012). MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. *Cancer research*, 72(13):3228–3237.
- Whirl-Carrillo, M., McDonagh, E., Hebert, J., Gong, L., Sangkuhl, K., Thorn, C., Altman, R., and Klein, T. E. (2012). Pharmacogenomics knowledge for personalized medicine. *Clinical pharmacology and therapeutics*, 92(4):414.
- Yadav, B., Pemovska, T., Szwajda, A., Kuleskiy, E., Kontro, M., Karjalainen, R., Majumder, M. M., Malani, D., Murumägi, A., Knowles, J., et al. (2014). Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. *Scientific reports*, 4.
- Yamanishi, Y., Pauwels, E., and Kotera, M. (2012). Drug side-effect prediction based on the integration of chemical and biological spaces. *J. Chem. Inf. Model.*, 52(12):3284–3292.
- Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2013). Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. *Nucleic Acids Res.*, 41(D1):D955–D961.
- Zhang, N., Wang, H., Fang, Y., Wang, J., Zheng, X., and Liu, X. S. (2015). Predicting anticancer drug responses using a dual-layer integrated cell line-drug network model. *PLoS Comput Biol*, 11(9):e1004498.
- Zhou, T., Shan, H., Banerjee, A., and Sapiro, G. (2012). Kernelized probabilistic matrix factorization: Exploiting graphs and side information. In *SDM*, volume 12, pages 403–414. SIAM.

## S1 Supplementary Material

### Case Study: GDSC Data Set

Below, we provide supplementary information of the data and results from the GDSC data set as discussed in the main text sections 3 and 4.

Table S1 shows the names, type and tissue of 124 cancer cell lines and names, primary targets of 124 drugs used in our study. We obtained these data from Genomics of Drug Sensitivity in Cancer project Yang et al. (2013), and show here for the purpose of motivating reproducibility of the results. For defining compact primary targets, we annotated their names so that they belong to one class of targets, for instance MEK1/2 were named to MEK. Table S2 list the 71 pathways used in the case study.

Table S3 shows the statistical significance of the predictive performances of *cuKBMF* compared to other methods on the GDSC data set. Figure S1 compares the predictive performance of *cuKBMF* with other methods on GDSC data, when learned with 10 components (see details in main text section 4). Figure S2 shows the variation of drug responses explained by the two components of the *cuKBMF* model. For component 1, the drug response pattern can be hypothesized in the following manner: the EGFR inhibitors showing a response to the set of cell lines (at the lower part), inhibit the EGFR activity which in turn inhibits the activation of the downstream signaling pathways, whereas the inhibitors showing no response to the cell lines (on the upper part) fail to inhibit the EGFR activation, resulting the downstream signaling pathways to be active.

Similarly for component 2, the MEK inhibitors showing response to the set of cell lines (at the lower part), inhibit the MEK activity,, whereas the inhibitors showing no response to the cell lines (on the upper part) fail to inhibit the MEK pathways.

	Cell line	Type	Tissue	Drug	Primary Target	Annotated Target
1	ES3	bone	ewings sarcoma	Erlotinib	EGFR	EGFR
2	ES5	bone	ewings sarcoma	Rapamycin	MTOR	MTOR
3	EW-11	bone	ewings sarcoma	Sumitinib	PDGFRA, PDGFRB, KDR, KIT, FLT3	PDGFR
4	NCI-H1395	lung	lung_NSLC adenocarcinoma	PHA-665752	MET	MET
5	NCI-H1770	lung	lung_NSLC not_specified	MG-132	Proteasome	Proteasome
6	DMS-114	lung	lung_small_cell carcinoma	Paclitaxel	Microtubules	Microtubules
7	NCI-H1092	lung	lung_small_cell carcinoma	Cyclophosphamide	SMO	SMO
8	NCI-H2141	lung	lung_small_cell carcinoma	AZ628	BRAF	BRAF
9	NCI-H345	lung	lung_small_cell carcinoma	Sorafenib	PDGFRA, PDGFRB, KDR, KIT, FLT3	PDGFR
10	NCI-H446	lung	lung_small_cell carcinoma	VX-680	Aurora A/B/C, FLT3, ABL1, JAK2	FLT3
11	NCI-H82	lung	lung_small_cell carcinoma	Imatinib	ABL, KIT, PDGFR	PDGFR
12	SK-N-DZ	nervous_system	neuroblastoma	NVP-TAE684	ALK	MET, ALK
13	Calu-6	lung	lung_NSLC adenocarcinoma	PF-02341066	MET, ALK	MET, ALK
14	LU-45	lung	lung_NSLC_large_cell	AZD-0530	SRC, ABL1	SRC
15	SHP-77	lung	lung_small_cell carcinoma	S-Trityl-L-cysteine	KIF11	KIF11
16	HCC1187	breast	breast	Z-LLNc-CHO	g-secretase	g-secretase
17	HCC2157	breast	breast	Dasatinib	ABL, SRC, KIT, PDGFR	SRC,ABL
18	HCC2218	breast	breast	GNF-2	BCR-ABL	SRC,ABL
19	BB49-HNC	aero_digestive_tract	head_and_neck	CGP-60474	CDK1/2/5/7/9	CDK
20	CPC-N	lung	lung_small_cell carcinoma	CGP-082996	CDK4	CDK
21	EC-GI-10	aero_digestive_tract	oesophagus	A-770041	SRC family	SRC,ABL
22	IM-9	blood	Myeloma	WH4-023	SRC family, ABL	SRC,ABL
23	IST-SL1	lung	lung_small_cell carcinoma	WZ-1-84	BMX	BMX
24	LB831-BLC	urogenital_system	Bladder	BI-2536	PLK1/2/3	PLK
25	LU-134-A	lung	lung_small_cell carcinoma	BMS-536924	IGF1R	IGF1R
26	MS-1	lung	lung_small_cell carcinoma	BMS-509744	ITK	ITK
27	MZ7-mel	skin	melanoma	Pyrimethamine	Dihydrofolate reductase (DHFR)	DHFR
28	NCI-H510A	lung	lung_small_cell carcinoma	JW-752-1	MTOR	MTOR
29	SK-MM-2	blood	Myeloma	A-443654	AKT1/2/3	AKT
30	TE-1	aero_digestive_tract	oesophagus	GW843682X	HDAC	PLK
31	TE-10	aero_digestive_tract	oesophagus	MS-275	HDAC	HDAC
32	HL-60	blood	acute_myeloid_leukaemia	Parthenolide	NFKB1	NFKB1
33	NCI-H226	lung	lung_NSLC_squamous_cell carcinoma	KIN001-135	IKKE	IKKE
34	NCI-H23	lung	lung_NSLC adenocarcinoma	TCX221	PI3K beta	PI3K
35	SR	blood	lymphoid_neoplasm_other	Bortezomib	Proteasome	Proteasome
36	UACC-257	skin	melanoma	XMD8-85	ERK5 (MK07)	ERK5
37	TK10	kidney	kidney	Roscovitine	CDKs	CDK
38	SF208	nervous_system	glioma	Suberoyl	GAD65-PP1C phosphatase	GAD65-PP1C phosphatase
39	KM12	digestive_system	large_intestine	Lapatinib	EGFR, ERBB2	EGFR
40	Becker	nervous_system	glioma	GSK269962A	ROCK	ROCK
41	697	blood	lymphoblastic leukemia	Doxorubicin	DNA intercalating	DNA
42	COR-L88	lung	lung_small_cell carcinoma	Etoposide	TOP2	TOP
43	COLO-824	breast	breast	Gemcitabine	DNA replication	DNA
44	DG-75	Burkitt_lymphoma	Burkitt_lymphoma	Mitomycin C	DNA crosslinker	DNA
45	DJM-1	skin	skin_other	Vinorelbine	Microtubules	Microtubules
46	DU-4475	breast	breast	NSC-87877	SHIP 2 (PTN6/11)	SHIP 2 (PTN6/11)
47	EB2	blood	Burkitt_lymphoma	Bicalutamide	Androgen receptor (ANDR)	ANDR
48	EB-3	blood	Burkitt_lymphoma	Midostaurin	KIT	PDGFR
49	GC1Y	digestive_system	stomach	CHIR-99021	GSK3B	GSK3B
50	GI-ME-N	nervous_system	neuroblastoma	AP-24534	ABL	SRC,ABL
51	GOTO	nervous_system	neuroblastoma	AZD6482	PI3Kb (P3C2B)	PI3K
52	GT3TKB	digestive_system	stomach	PF-562271	FAK	FAK
53	HEL	blood	acute_myeloid_leukaemia	DMOG	Prolyl-4-Hydroxylase	Hydroxylase
54	IHI	T_cell_leukemia	T_cell_leukemia	FTI-277	Farnesyl transferase (FNTA)	FNTA
55	HT	blood	B_cell_lymphoma	OSU-03012	PDK1 (PDPK1)	PDK1
56	IST-MIES1	lung	mesothelioma	Shikonin	unknown	unknown
57	JiyoyeP-2003	blood	Burkitt_lymphoma	AKT inhibitor VIII	AKT1/2	AKT
58	JVM-2	blood	lymphoid_neoplasm_other	Embelin	XIAP	XIAP
59	KARPAS-299	blood	anaplastic_large_cell_lymphoma	FH535	unknown	unknown
60	KARPAS-422	blood	B_cell_lymphoma	PAC-1	CASP3 activator	CASP3
61	KINGS-1	nervous_system	glioma	IPA-3	PAK	PAK
62	KM12E-2	nervous_system	acute_myeloid_leukaemia	GSK-650394	GSK3	GSK3
63	KP-N-YN	nervous_system	neuroblastoma	BAY 61-3606	SYK	SYK
64	L-428	blood	Hodgkin_lymphoma	Thapsigargin	ATPase, Ca++ transporting, cardiac muscle, slow twitch 2	ATPase
65	L-540	blood	Hodgkin_lymphoma	Obatoclax Mesylate	BCL-2, BCL-XL, MCL-1	BCL
66	LNCaP-Clone-FGC	urogenital_system	prostate	BMS-754807	IGF1R	IGF1R
67	LS-123	digestive_system	large_intestine	OSI-906	IGF1R	IGF1R
68	LS-411N	digestive_system	large_intestine	Boxacortene	Retinoic acid X family agonist	Retinoic
69	LS-513	digestive_system	large_intestine	Bleomycin	DNA damage	DNA
70	MBH-PREB-1	blood	B_cell_leukemia	LFM-A13	RTK	RTK
71	ML-2	blood	acute_myeloid_leukaemia	ATY922	HSP90	HSP90
72	MN-60	blood	B_cell_leukemia	Bryostatins 1	PRKC	PRKC
73	MONO-MAC-6	blood	acute_myeloid_leukaemia	Pazopanib	VEGFR, PDGFRA, PDGFRB, KIT	PDGFR
74	MPP-89	lung	mesothelioma	LAQ824	HDAC	HDAC
75	NCI-SNU-5	digestive_system	stomach	Epothilone B	Microtubules	Microtubules
76	NCI-SNU-16	digestive_system	stomach	GSK-1904529A	IGF1R	IGF1R
77	NH-12	nervous_system	neuroblastoma	Tipifarnib	Farnesyl-transferase (FNTA)	FNTA
78	NMC-G1	nervous_system	glioma	AS601245	JNK	JNK
79	no-11	nervous_system	glioma	AICAR	AMPK agonist	AMPK
80	NOMO-1	blood	acute_myeloid_leukaemia	Camptothecin	TOP1	TOP
81	NCI-H524	lung	lung_small_cell carcinoma	Vinblastine	Microtubules	Microtubules
82	P30-OHK	blood	lymphoblastic leukemia	Cisplatin	DNA crosslinker	DNA
83	P31-FUJ	blood	acute_myeloid_leukaemia	Cytarabine	DNA synthesis	DNA
84	PF-382	blood	lymphoblastic_T_cell_leukaemia	Docetaxel	Microtubules	Microtubules
85	Raji	blood	Burkitt_lymphoma	Methotrexate	Dihydrofolate reductase (DHFR)	DHFR
86	REH	blood	B_cell_leukemia	ATRA	Retinoic acid and retinoid X receptor agonist	Retinoic
87	SF126	nervous_system	glioma	Gedfinib	RET	RET
88	SJSA-1	bone	bone_other	ABT-263	BCL2, BCL-XL, BCL-W	BCL
89	SK-NP-1	kidney	kidney	Vorinostat	HDAC inhibitor Class I, IIa, IIb, IV	HDAC
90	SW684	soft_tissue	fibrosarcoma	Nilotinib	ABL	SRC,ABL
91	SW872	soft_tissue	soft_tissue_other	RDEA119	MEK1/2	MEK
92	SW962	urogenital_system	urogenital_system_other	CI-1040	MEK1/2	MEK
93	TUR	blood	B_cell_lymphoma	Teniposide	MTOR	MTOR
94	U-698-M	blood	B_cell_leukemia	AZD-2281	PARP1/2	PARP
95	WSU-NHL	blood	lymphoid_neoplasm_other	ABT-888	PARP1/2	PARP
96	RCC10RGB	kidney	kidney	Bosutinib	SRC, ABL, TEC	SRC,ABL
97	KURAMOCHI	urogenital_system	ovary	Lenalidomide	TNF alpha	TNF
98	Ramos-2G6-4C10	blood	Burkitt_lymphoma	Acitinib	PDGFR, KIT, VEGFR	PDGFR
99	CW-2	digestive_system	large_intestine	CEP-701	FLT3, JAK2, NTRK1, RET	FLT3
100	COLO-320-HSR	digestive_system	large_intestine	17-AAG	HSP90	HSP90
101	COLO-684	urogenital_system	endometrium	VX-702	s8	JNK
102	CA46	blood	Burkitt_lymphoma	AMG-706	VEGFR, RET, c-KIT, PDGFR	PDGFR
103	RL	blood	B_cell_lymphoma	KU-55933	ATM	ATM
104	SNU-C1	digestive_system	large_intestine	BIBW2992	EGFR, ERBB2	EGFR
105	ST486	blood	Burkitt_lymphoma	GDC-0449	SMO	SMO
106	BC-1	blood	B_cell_lymphoma	PLX4720	BRAF	BRAF
107	CAS-1	nervous_system	glioma	BX-705	TBK1, PDK1, IKK, AURKB/C	PDK1
108	MPM-223	breast	breast	NU-7441	DNAPK	DNAPK
109	LS-1034	digestive_system	large_intestine	BIBB-0796	p38, JNK2	JNK
110	HDLM-2	blood	Hodgkin_lymphoma	JNK Inhibitor VIII	JNK	JNK
111	KNS-S1-FD	nervous_system	glioma	681640	WEE1, CHK1	CHK1
112	TE-6	aero_digestive_tract	oesophagus	Nutlin-3a	MDM2	MDM
113	TE-12	aero_digestive_tract	oesophagus	PD-173074	FGFR1/3	FGFR
114	D-263MG	nervous_system	glioma	ZM-447439	AURKB	PDK1
115	D-502MG	nervous_system	glioma	RO-3306	CDK1	CDK
116	EW-3	bone	ewings sarcoma	PD-032591	CDK4/6	CDK
117	EW-4	bone	ewings sarcoma	GDC0067	GDC0067 (class 1)	PDK
118	EW-18	bone	ewings sarcoma	PD-032591	MEK1/2	MEK
119	EW-24	bone	ewings sarcoma	SB590885	BRAF	BRAF
120	LAN-6	nervous_system	neuroblastoma	AZD6244	MEK1/2	MEK
121	NB10	nervous_system	neuroblastoma	BMS-708163	gamma-secretase	G-secretase
122	NB6	nervous_system	neuroblastoma	JNJ-26854165	MDM2	MDM
123	NB5	nervous_system	neuroblastoma	TW 37	BCL-2, BCL-XL	BCL
124	NB14	nervous_system	neuroblastoma	AG-014699	PARP1, PARP2	PARP

Table S1: Cell lines and drugs used in the GDSC case study.

Pathway Name	Reference
1 BIOCARTA_EGFR_SMRTF_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/BIOCARTA_EGFR_SMRTF_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/BIOCARTA_EGFR_SMRTF_PATHWAY</a>
2 PID_VEGF_VEGFR_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/PID_VEGF_VEGFR_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/PID_VEGF_VEGFR_PATHWAY</a>
3 REACTOME_SIGNALING_BY_EGFR_IN_CANCER	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_SIGNALING_BY_EGFR_IN_CANCER">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_SIGNALING_BY_EGFR_IN_CANCER</a>
4 REACTOME_EGFR_DOWNREGULATION	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_EGFR_DOWNREGULATION">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_EGFR_DOWNREGULATION</a>
5 REACTOME_SHC1_EVENTS_IN_EGFR_SIGNALING	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_SHC1_EVENTS_IN_EGFR_SIGNALING">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_SHC1_EVENTS_IN_EGFR_SIGNALING</a>
6 KEGG_MTOR_SIGNALING_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/KEGG_MTOR_SIGNALING_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/KEGG_MTOR_SIGNALING_PATHWAY</a>
7 BIOCARTA_MTOR_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/BIOCARTA_MTOR_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/BIOCARTA_MTOR_PATHWAY</a>
8 BIOCARTA_IKGF1R_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/BIOCARTA_IKGF1R_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/BIOCARTA_IKGF1R_PATHWAY</a>
9 PID_MTOR_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/PID_MTOR_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/PID_MTOR_PATHWAY</a>
10 REACTOME_ENERGY_DEPENDENT_REGULATION_OF_MTOR_BY_LKB1_AMPK	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_ENERGY_DEPENDENT_REGULATION_OF_MTOR_BY_LKB1_AMPK">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_ENERGY_DEPENDENT_REGULATION_OF_MTOR_BY_LKB1_AMPK</a>
11 PID_KIT_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/PID_KIT_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/PID_KIT_PATHWAY</a>
12 REACTOME_REGULATION_OF_KIT_SIGNALING	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_REGULATION_OF_KIT_SIGNALING">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_REGULATION_OF_KIT_SIGNALING</a>
13 BIOCARTA_MET_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/BIOCARTA_MET_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/BIOCARTA_MET_PATHWAY</a>
14 PID_MET_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/PID_MET_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/PID_MET_PATHWAY</a>
15 BIOCARTA_AKT_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/BIOCARTA_AKT_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/BIOCARTA_AKT_PATHWAY</a>
16 PID_PI3K_AKT_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/PID_PI3K_AKT_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/PID_PI3K_AKT_PATHWAY</a>
17 REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_NEGATIVE_REGULATION_OF_THE_PI3K_AKT_NETWORK</a>
18 REACTOME_PI3K_AKT_ACTIVATION	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_PI3K_AKT_ACTIVATION">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_PI3K_AKT_ACTIVATION</a>
19 REACTOME_AKT_PHOSPHORYLATES_TARGETS_IN_THE_CYTOSOL	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_AKT_PHOSPHORYLATES_TARGETS_IN_THE_CYTOSOL">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_AKT_PHOSPHORYLATES_TARGETS_IN_THE_CYTOSOL</a>
20 REACTOME_CDN_DEPENDENT_PI3K_AKT_SIGNALING	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_CDN_DEPENDENT_PI3K_AKT_SIGNALING">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_CDN_DEPENDENT_PI3K_AKT_SIGNALING</a>
21 REACTOME_PIP2_ACTIVATES_AKT_SIGNALING	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_PIP2_ACTIVATES_AKT_SIGNALING">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_PIP2_ACTIVATES_AKT_SIGNALING</a>
22 BIOCARTA_HDAC_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/BIOCARTA_HDAC_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/BIOCARTA_HDAC_PATHWAY</a>
23 PID_HDAC_CLASSIII_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/PID_HDAC_CLASSIII_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/PID_HDAC_CLASSIII_PATHWAY</a>
24 PID_HDAC_CLASSIII_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/PID_HDAC_CLASSIII_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/PID_HDAC_CLASSIII_PATHWAY</a>
25 PID_HDAC_CLASSI_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/PID_HDAC_CLASSI_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/PID_HDAC_CLASSI_PATHWAY</a>
26 PID_ERBB2_ERBB3_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/PID_ERBB2_ERBB3_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/PID_ERBB2_ERBB3_PATHWAY</a>
27 REACTOME_DOWNREGULATION_OF_ERBB2_ERBB3_SIGNALING	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_DOWNREGULATION_OF_ERBB2_ERBB3_SIGNALING">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_DOWNREGULATION_OF_ERBB2_ERBB3_SIGNALING</a>
28 REACTOME_GBR2_EVENTS_IN_ERBB2_SIGNALING	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_GBR2_EVENTS_IN_ERBB2_SIGNALING">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_GBR2_EVENTS_IN_ERBB2_SIGNALING</a>
29 REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING</a>
30 ST_JNK_MAPK_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/ST_JNK_MAPK_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/ST_JNK_MAPK_PATHWAY</a>
31 PID_TCR_JNK_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/PID_TCR_JNK_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/PID_TCR_JNK_PATHWAY</a>
32 REACTOME_JNK_C_JUN_KINASES_PHOSPHORYLATION_AND_ACTIVATION_MEDIATED_BY_ACTIVATED_HUMAN_TAK1	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_JNK_C_JUN_KINASES_PHOSPHORYLATION_AND_ACTIVATION_MEDIATED_BY_ACTIVATED_HUMAN_TAK1">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_JNK_C_JUN_KINASES_PHOSPHORYLATION_AND_ACTIVATION_MEDIATED_BY_ACTIVATED_HUMAN_TAK1</a>
33 BIOCARTA_ATM_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/BIOCARTA_ATM_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/BIOCARTA_ATM_PATHWAY</a>
34 PID_ATM_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/PID_ATM_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/PID_ATM_PATHWAY</a>
35 REACTOME_IRAK1_RECRUITS_IKK_COMPLEX	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_IRAK1_RECRUITS_IKK_COMPLEX">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_IRAK1_RECRUITS_IKK_COMPLEX</a>
36 REACTOME_ACTIVATION_OF_IKK1_BY_IKK_EPSILON	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_ACTIVATION_OF_IKK1_BY_IKK_EPSILON">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_ACTIVATION_OF_IKK1_BY_IKK_EPSILON</a>
37 REACTOME_IKK_COMPLEX_RECRUITMENT_MEDIATED_BY_IKK1	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_IKK_COMPLEX_RECRUITMENT_MEDIATED_BY_IKK1">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_IKK_COMPLEX_RECRUITMENT_MEDIATED_BY_IKK1</a>
38 REACTOME_NEGATIVE_REGULATION_OF_FGFR_SIGNALING	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_NEGATIVE_REGULATION_OF_FGFR_SIGNALING">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_NEGATIVE_REGULATION_OF_FGFR_SIGNALING</a>
39 REACTOME_SIGNALING_BY_FGFR_IN_DISEASE	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_SIGNALING_BY_FGFR_IN_DISEASE">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_SIGNALING_BY_FGFR_IN_DISEASE</a>
40 REACTOME_SIGNALING_BY_FGFR_MUTANTS	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_SIGNALING_BY_FGFR_MUTANTS">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_SIGNALING_BY_FGFR_MUTANTS</a>
41 REACTOME_FGFR_LIGAND_BINDING_AND_ACTIVATION	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_FGFR_LIGAND_BINDING_AND_ACTIVATION">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_FGFR_LIGAND_BINDING_AND_ACTIVATION</a>
42 PID_IL2_PIRK_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/PID_IL2_PIRK_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/PID_IL2_PIRK_PATHWAY</a>
43 PID_PIRK_PLC_TBS_PATHWAY	<a href="http://www.broadinstitute.org/gen/taqpath/cards/PID_PIRK_PLC_TBS_PATHWAY">http://www.broadinstitute.org/gen/taqpath/cards/PID_PIRK_PLC_TBS_PATHWAY</a>
44 REACTOME_PI3K_EVENTS_IN_ERBB4_SIGNALING	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_PI3K_EVENTS_IN_ERBB4_SIGNALING">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_PI3K_EVENTS_IN_ERBB4_SIGNALING</a>
45 REACTOME_PI3K_CASCADE	<a href="http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_PI3K_CASCADE">http://www.broadinstitute.org/gen/taqpath/cards/REACTOME_PI3K_CASCADE</a>
46 EGFR_UP.V1_DN	<a href="http://www.broadinstitute.org/gen/taqpath/cards/EGFR_UP.V1_DN">http://www.broadinstitute.org/gen/taqpath/cards/EGFR_UP.V1_DN</a>
47 EGFR_UP.V1_UP	<a href="http://www.broadinstitute.org/gen/taqpath/cards/EGFR_UP.V1_UP">http://www.broadinstitute.org/gen/taqpath/cards/EGFR_UP.V1_UP</a>
48 AKT_UP_MTOR_DN.V1_DN	<a href="http://www.broadinstitute.org/gen/taqpath/cards/AKT_UP_MTOR_DN.V1_DN">http://www.broadinstitute.org/gen/taqpath/cards/AKT_UP_MTOR_DN.V1_DN</a>
49 AKT_UP_MTOR_DN.V1_UP	<a href="http://www.broadinstitute.org/gen/taqpath/cards/AKT_UP_MTOR_DN.V1_UP">http://www.broadinstitute.org/gen/taqpath/cards/AKT_UP_MTOR_DN.V1_UP</a>
50 MTOR_UP.V1_DN	<a href="http://www.broadinstitute.org/gen/taqpath/cards/MTOR_UP.V1_DN">http://www.broadinstitute.org/gen/taqpath/cards/MTOR_UP.V1_DN</a>
51 MTOR_UP.V1_UP	<a href="http://www.broadinstitute.org/gen/taqpath/cards/MTOR_UP.V1_UP">http://www.broadinstitute.org/gen/taqpath/cards/MTOR_UP.V1_UP</a>
52 MTOR_UP.V1.DN	<a href="http://www.broadinstitute.org/gen/taqpath/cards/MTOR_UP.V1.DN">http://www.broadinstitute.org/gen/taqpath/cards/MTOR_UP.V1.DN</a>
53 MTOR_UP.V1.V1_UP	<a href="http://www.broadinstitute.org/gen/taqpath/cards/MTOR_UP.V1.V1_UP">http://www.broadinstitute.org/gen/taqpath/cards/MTOR_UP.V1.V1_UP</a>
54 JAK2_DN.V1_DN	<a href="http://www.broadinstitute.org/gen/taqpath/cards/JAK2_DN.V1_DN">http://www.broadinstitute.org/gen/taqpath/cards/JAK2_DN.V1_DN</a>
55 JAK2_DN.V1_UP	<a href="http://www.broadinstitute.org/gen/taqpath/cards/JAK2_DN.V1_UP">http://www.broadinstitute.org/gen/taqpath/cards/JAK2_DN.V1_UP</a>
56 ALK_DN.V1_DN	<a href="http://www.broadinstitute.org/gen/taqpath/cards/ALK_DN.V1_DN">http://www.broadinstitute.org/gen/taqpath/cards/ALK_DN.V1_DN</a>
57 ALK_DN.V1_UP	<a href="http://www.broadinstitute.org/gen/taqpath/cards/ALK_DN.V1_UP">http://www.broadinstitute.org/gen/taqpath/cards/ALK_DN.V1_UP</a>
58 SRC_UP.V1_DN	<a href="http://www.broadinstitute.org/gen/taqpath/cards/SRC_UP.V1_DN">http://www.broadinstitute.org/gen/taqpath/cards/SRC_UP.V1_DN</a>
59 SRC_UP.V1_UP	<a href="http://www.broadinstitute.org/gen/taqpath/cards/SRC_UP.V1_UP">http://www.broadinstitute.org/gen/taqpath/cards/SRC_UP.V1_UP</a>
60 AKT_UP.V1_DN	<a href="http://www.broadinstitute.org/gen/taqpath/cards/AKT_UP.V1_DN">http://www.broadinstitute.org/gen/taqpath/cards/AKT_UP.V1_DN</a>
61 AKT_UP.V1_UP	<a href="http://www.broadinstitute.org/gen/taqpath/cards/AKT_UP.V1_UP">http://www.broadinstitute.org/gen/taqpath/cards/AKT_UP.V1_UP</a>
62 JNK_DN.V1_DN	<a href="http://www.broadinstitute.org/gen/taqpath/cards/JNK_DN.V1_DN">http://www.broadinstitute.org/gen/taqpath/cards/JNK_DN.V1_DN</a>
63 JNK_DN.V1_UP	<a href="http://www.broadinstitute.org/gen/taqpath/cards/JNK_DN.V1_UP">http://www.broadinstitute.org/gen/taqpath/cards/JNK_DN.V1_UP</a>
64 MEK_UP.V1_DN	<a href="http://www.broadinstitute.org/gen/taqpath/cards/MEK_UP.V1_DN">http://www.broadinstitute.org/gen/taqpath/cards/MEK_UP.V1_DN</a>
65 MEK_UP.V1_UP	<a href="http://www.broadinstitute.org/gen/taqpath/cards/MEK_UP.V1_UP">http://www.broadinstitute.org/gen/taqpath/cards/MEK_UP.V1_UP</a>
66 ATM_DN.V1_DN	<a href="http://www.broadinstitute.org/gen/taqpath/cards/ATM_DN.V1_DN">http://www.broadinstitute.org/gen/taqpath/cards/ATM_DN.V1_DN</a>
67 ATM_DN.V1_UP	<a href="http://www.broadinstitute.org/gen/taqpath/cards/ATM_DN.V1_UP">http://www.broadinstitute.org/gen/taqpath/cards/ATM_DN.V1_UP</a>
68 TBK1.DF_DN	<a href="http://www.broadinstitute.org/gen/taqpath/cards/TBK1.DF_DN">http://www.broadinstitute.org/gen/taqpath/cards/TBK1.DF_DN</a>
69 TBK1.DF_UP	<a href="http://www.broadinstitute.org/gen/taqpath/cards/TBK1.DF_UP">http://www.broadinstitute.org/gen/taqpath/cards/TBK1.DF_UP</a>
70 TBK1.DN.6SHS_DN	<a href="http://www.broadinstitute.org/gen/taqpath/cards/TBK1.DN.6SHS_DN">http://www.broadinstitute.org/gen/taqpath/cards/TBK1.DN.6SHS_DN</a>
71 TBK1.DN.6SHS_UP	<a href="http://www.broadinstitute.org/gen/taqpath/cards/TBK1.DN.6SHS_UP">http://www.broadinstitute.org/gen/taqpath/cards/TBK1.DN.6SHS_UP</a>

Table S2: List of pathways used in the GDSC case study. Some of the names are modified so that they can fit into the eye diagram (main text Figure 5). For example, reactome SHC1 events in EGFR signaling is modified as re:SHC1 event events in EGFR signaling.






Figure S1: Comparison of *cwKBMF* with other methods on GDSC data. Spearman rank correlation between the predictions and the response data, for each drug are calculated for each method. The correlations from each method (x-axis) are compared to those from *cwKBMF* (y-axis) with components 10. Each dot represents cross validated prediction performance for a drug response averaged over 10 random rounds of 5 fold cross-validation procedure. The subscript in method's name denotes the format of learning data used by the methods; *single-view* means that the method is learned using one view (i.e, one group containing all the genomic features), while *multi-view* means that the method is learned using multiple views (i.e., genomic features are grouped into many views based on the prior knowledge about the pathways). Method abbreviation: *cwKBMF*, kernelized Bayesian matrix factorization with component-wise MKL; *KBMF*, kernelized Bayesian matrix factorization; *BMTMKL*, Bayesian multi-task MKL; *KPMF*, kernelized probabilistic matrix factorization; *MT-LR*, multi-task sparse linear regression; *Baseline*, mean of the training data. P-values show the statistical significance of the improvements of *cwKBMF*'s predictions compared to other methods computed with one-sided paired Wilcoxon Sign-Rank test.




Figure S2: Variation in drug responses explained by *cwKBMF* components. Component 1 explains EGFR inhibitors and component 2 models MEK inhibitors. The heat map (in center) shows the actual drug responses of the inhibitors (x-axis), on top 10 cancer cell lines (y.axis). Bar plots on x- and y- axis, indicate the weights of the inhibitors and cell lines learned by the *cwKBMF* method, respectively. FH535 (with unknown primary target) explained by component 2, shows variations in responses similar to MEK inhibitors.

Table S3: Statistical significance of the predictive performances on the GDSC data set. P-values from one-sided paired Wilcoxon Sign-Rank test corresponding to the curves shown in Figure 2 (in the main text), corrected for multiple testing using Benjamini, Hochberg, and Yekutieli’s method Benjamini and Hochberg (1995), Benjamini and Yekutieli (2001).

Methods	$cwKBMF_{single-view}$	$cwKBMF_{multi-view}$
$cwKBMF_{single-view}$	—	$1.369 \times 10^{-6}$
$KBMF_{multi-view}$	—	$1.369 \times 10^{-6}$
$BMTMKL_{multi-view}$	—	$2.922 \times 10^{-2}$
$KPMF_{single-view}$	$1.369 \times 10^{-6}$	$1.369 \times 10^{-6}$
$MT-LR_{single-view}$	$2.017 \times 10^{-4}$	$2.790 \times 10^{-5}$
Baseline	$1.369 \times 10^{-6}$	$1.369 \times 10^{-6}$

## Case Study: CTRP Data Set

Below, we provides supplementary information of the data and results from the CTRP data set as discussed in the main text section 3 and 4.

Table S4 shows the names, types and tissues of 66 cancer cell lines and names, primary targets of 63 drugs used in our study. We obtained these data from Cancer Therapeutic Response Portal Basu et al. (2013), and show here for the purpose of motivating reproducibility of the results. Table S5 list the 25 pathways used in the case study.

Table S6 shows the statistical significance of the predictive performances of *cwKBMF* compared to other methods on the GDSC data set. Figure S3 compares the predictive performance of *cwKBMF* with other methods on CTRP data, when learned with 20 components.

	Cell line	Type	Tissue	Drug	Primary Target
1	A2780	OVARY		etoposide	TOP2A;TOP2B
2	A375	SKIN		oligomycin A	ATP5L2
3	AMO1	HEMATOPOIETIC_AND_LYMPHOID_TISSUE	PLASMA_CELL_MYELOMA	chaetocin	SUV39H1
4	BL70	HEMATOPOIETIC_AND_LYMPHOID_TISSUE		tubastatin A	HDAC6
5	CAL12T	LUNG	NON_SMALL_CELL_CARCCINOMA	avrainvillamide	NPM1
6	COLO320	LARGE_INTESTINE		TG-101348	JAK2
7	COLO678	LARGE_INTESTINE		SCH-79797	F2R
8	CORL23	LUNG	LARGE_CELL_CARCCINOMA	HLI 373	MDM2
9	COV318	OVARY		indisulam	CA9
10	EFO27	OVARY		Compound 10b	MAP3K8
11	GAMG	CENTRAL_NERVOUS_SYSTEM		BMS-536924	IGF1R;INSR
12	HCC15	LUNG	SQUAMOUS_CELL_CARCCINOMA	Compound 12	NOS2
13	HCC2935	LUNG	NON_SMALL_CELL_CARCCINOMA	JZL-184	MGLL
14	HCC4006	LUNG	ADENOCARCINOMA	cerulenin	FASN;HMGCS1
15	HCC827	LUNG	ADENOCARCINOMA	pemetrexed	TS;DHFR;GART
16	HCT116	LARGE_INTESTINE		serdemetan	MDM2
17	HEC151	ENDOMETRIUM		tipifarnib-P1	FNTA
18	HEC59	ENDOMETRIUM		ATRA	RARA;RARB;RARG
19	HEPG2	LIVER		SNX-2112	HSP90AA1;HSP90B1
20	HSS52T	SKIN		BRD4770	EHMT2
21	HT1080	SOFT_TISSUE		NSC632839	USP5;USP13
22	HT29	LARGE_INTESTINE		WT-101	HDAC6
23	IGROV1	OVARY		vorinostat	AGTR2
24	JHH6	LIVER		batimustat	HDAC1;HDAC2;HDAC3;HDAC6;HDAC8
25	JHOS4	OVARY		PF-750	MMP1;MMP2;MMP3;MMP7;MMP9
26	JHUEM2	ENDOMETRIUM		PF-750	FAAH
27	KLE	ENDOMETRIUM		2-bromopyruvate	HK2
28	KMS11	HEMATOPOIETIC_AND_LYMPHOID_TISSUE	PLASMA_CELL_MYELOMA	AC55649	RARB
29	LN229	CENTRAL_NERVOUS_SYSTEM		necrostatin-1	RIPK1
30	LP1	HEMATOPOIETIC_AND_LYMPHOID_TISSUE	PLASMA_CELL_MYELOMA	PX-12	TXN
31	LS123	LARGE_INTESTINE		nimodipine	CACNA1C;CACNA1D;CACNA1S;CACNA1F
32	MCF7	BREAST		lovastatin acid	HMGCR
33	MKN74	STOMACH		GW-405833	CB2
34	NCH1694	LUNG	SMALL_CELL_CARCCINOMA	minoxidil	KCNJ8;KCNJ11
35	NCH1915	LUNG	LARGE_CELL_CARCCINOMA	PRIMA-1	TP53
36	NCH2023	LUNG	ADENOCARCINOMA	CR-1-31B	EIF4A2;EIF4E;EIF4G1
37	NCH2030	LUNG	NON_SMALL_CELL_CARCCINOMA	CHEMBL399379	ACLY
38	NCH2122	LUNG	ADENOCARCINOMA	sildenafil	PDE5A
39	NCH2172	LUNG	NON_SMALL_CELL_CARCCINOMA	schmetinib	MAP2K1;MAP2K2
40	NCH2286	LUNG	SMALL_CELL_CARCCINOMA	TGX-115	PIK3CB;PIK3CD
41	NCH3255	LUNG	ADENOCARCINOMA	10-DEBC	AKT
42	NCH441	LUNG	ADENOCARCINOMA	BML-259	CDK5;CDK2
43	NCH460	LUNG	LARGE_CELL_CARCCINOMA	PF-04217903	MET
44	OCLY10	HEMATOPOIETIC_AND_LYMPHOID_TISSUE	DIFFUSE_LARGE_B_CELL_LYPHOMA	purnmorphamine	SMO
45	OV90	OVARY		RG-108	DNMT1
46	OVCAR4	OVARY		tosedostat	LAP3;NPEPPS;ANPEP
47	OVCAR8	OVARY		efornithine	ODC1
48	OVMANA	OVARY		LY-2365109	SLC6A9
49	PATU8902	PANCREAS		ML090	NOX1
50	PC3	PROSTATE		bovinocidin	SDHA;SDHB;SDHC;SDHD
51	RKN	SOFT_TISSUE		irosustat	STS
52	RKO	LARGE_INTESTINE		Compound 2	BCAT1
53	SCC9	UPPER_AERODIGESTIVE_TRACT		importazole	KPNB1
54	SKLU1	LUNG	ADENOCARCINOMA	YK 4-279	DHX9;ERG;ETV1
55	SKMEL5	SKIN		AG14361	PARP1
56	SNMG	ENDOMETRIUM		narciclasine	RHOA
57	SNU398	LIVER		3-amino benzamide	PARP1
58	SNU449	LIVER		B02	RAD51
59	SQ1	LUNG	SQUAMOUS_CELL_CARCCINOMA	PJ 34	PARP1
60	SUDHL4	HEMATOPOIETIC_AND_LYMPHOID_TISSUE	DIFFUSE_LARGE_B_CELL_LYPHOMA	BRD8909	STK33
61	SW480	LARGE_INTESTINE		MK-2206	AKT
62	SW620	LARGE_INTESTINE		MLN2238	PSMB5
63	T3M10	LUNG	LARGE_CELL_CARCCINOMA	CAY10618	NAMPT
64	TYKNU	OVARY		NA	NA
65	U2OS	BONE		NA	NA
66	U937	HEMATOPOIETIC_AND_LYMPHOID_TISSUE	DIFFUSE_LARGE_B_CELL_LYPHOMA	NA	NA

Table S4: Cell lines and drugs used in the CTRP case study.

Pathway Name	Reference
1 BIOCARTA_AKT_PATHWAY	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_AKT_PATHWAY">http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_AKT_PATHWAY</a>
2 PID_P13KCI_AKT_PATHWAY	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/PID_P13KCI_AKT_PATHWAY">http://www.broadinstitute.org/gsea/msigdb/cards/PID_P13KCI_AKT_PATHWAY</a>
3 REACTOME_NEGATIVE_REGULATION_OF_THE_P13K_AKT_NETWORK	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_NEGATIVE_REGULATION_OF_THE_P13K_AKT_NETWORK">http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_NEGATIVE_REGULATION_OF_THE_P13K_AKT_NETWORK</a>
4 REACTOME_P13K_AKT_ACTIVATION	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_P13K_AKT_ACTIVATION">http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_P13K_AKT_ACTIVATION</a>
5 REACTOME_AKT_PHOSPHORYLATES_TARGETS_IN_THE_CYTOSOL	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_AKT_PHOSPHORYLATES_TARGETS_IN_THE_CYTOSOL">http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_AKT_PHOSPHORYLATES_TARGETS_IN_THE_CYTOSOL</a>
6 REACTOME_CD28_DEPENDENT_P13K_AKT_SIGNALING	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_CD28_DEPENDENT_P13K_AKT_SIGNALING">http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_CD28_DEPENDENT_P13K_AKT_SIGNALING</a>
7 REACTOME_P13K_ACTIVATES_AKT_SIGNALING	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_P13K_ACTIVATES_AKT_SIGNALING">http://www.broadinstitute.org/gsea/msigdb/cards/REACTOME_P13K_ACTIVATES_AKT_SIGNALING</a>
8 BIOCARTA_MET_PATHWAY	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_MET_PATHWAY">http://www.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_MET_PATHWAY</a>
9 PID_MET_PATHWAY	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/PID_MET_PATHWAY">http://www.broadinstitute.org/gsea/msigdb/cards/PID_MET_PATHWAY</a>
10 PID_RHOA_PATHWAY	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/PID_RHOA_PATHWAY">http://www.broadinstitute.org/gsea/msigdb/cards/PID_RHOA_PATHWAY</a>
11 PID_RHOA_REG_PATHWAY	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/PID_RHOA_REG_PATHWAY">http://www.broadinstitute.org/gsea/msigdb/cards/PID_RHOA_REG_PATHWAY</a>
12 JAK2_DN.V1_DN	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/JAK2_DN.V1_DN">http://www.broadinstitute.org/gsea/msigdb/cards/JAK2_DN.V1_DN</a>
13 JAK2_DN.V1_UP	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/JAK2_DN.V1_UP">http://www.broadinstitute.org/gsea/msigdb/cards/JAK2_DN.V1_UP</a>
14 EIF4E_DN	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/EIF4E_DN">http://www.broadinstitute.org/gsea/msigdb/cards/EIF4E_DN</a>
15 EIF4E_UP	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/EIF4E_UP">http://www.broadinstitute.org/gsea/msigdb/cards/EIF4E_UP</a>
16 AKT_UP_MTOR_DN.V1_DN	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP_MTOR_DN.V1_DN">http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP_MTOR_DN.V1_DN</a>
17 AKT_UP_MTOR_DN.V1_UP	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP_MTOR_DN.V1_UP">http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP_MTOR_DN.V1_UP</a>
18 AKT_UP.V1_DN	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP.V1_DN">http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP.V1_DN</a>
19 AKT_UP.V1_UP	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP.V1_UP">http://www.broadinstitute.org/gsea/msigdb/cards/AKT_UP.V1_UP</a>
20 STK33_DN	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/STK33_DN">http://www.broadinstitute.org/gsea/msigdb/cards/STK33_DN</a>
21 STK33_NOMO_DN	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/STK33_NOMO_DN">http://www.broadinstitute.org/gsea/msigdb/cards/STK33_NOMO_DN</a>
22 STK33_NOMO_UP	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/STK33_NOMO_UP">http://www.broadinstitute.org/gsea/msigdb/cards/STK33_NOMO_UP</a>
23 STK33_SKM_DN	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/STK33_SKM_DN">http://www.broadinstitute.org/gsea/msigdb/cards/STK33_SKM_DN</a>
24 STK33_SKM_UP	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/STK33_SKM_UP">http://www.broadinstitute.org/gsea/msigdb/cards/STK33_SKM_UP</a>
25 STK33_UP	<a href="http://www.broadinstitute.org/gsea/msigdb/cards/STK33_UP">http://www.broadinstitute.org/gsea/msigdb/cards/STK33_UP</a>

Table S5: List of pathways used in the CTRP case study

Table S6: Statistical significance of the predictive performances on the CTRP data set. P-values from one-sided paired Wilcoxon Sign-Rank test corresponding to the curves shown in Figure 2 in the main text, corrected for multiple testing using Benjamini, Hochberg, and Yekutieli’s method Benjamini and Hochberg (1995), Benjamini and Yekutieli (2001).

Methods	$cwKBMF_{single-view}$	$cwKBMF_{multi-view}$
$cwKBMF_{single-view}$	—	$3.662 \times 10^{-4}$
$KBMF_{multi-view}$	—	$1.464 \times 10^{-3}$
$BMTMKL_{multi-view}$	—	$1.708 \times 10^{-3}$
$KPMF_{single-view}$	$3.662 \times 10^{-4}$	$3.662 \times 10^{-4}$
$MT-LR_{single-view}$	$7.324 \times 10^{-4}$	$3.662 \times 10^{-4}$
Baseline	$3.662 \times 10^{-4}$	$3.662 \times 10^{-4}$




Figure S3: Comparison of *cwKBMF* with other methods on CTRP data set. Spearman rank correlation between the predictions and the response data, for each drug are calculated for each method. The correlations from each method (x-axis) are compared to those from *cwKBMF* (y-axis) with components 10. Each dot represents cross validated prediction performance for a drug response averaged over 10 random rounds of 5 fold cross-validation procedure. The subscript in method's name denotes the format of learning data used by the methods; *single-view* means that the method is learned using one view (i.e, one group containing all the genomic features), while *multi-view* means that the method is learned using multiple views (i.e., genomic features are grouped into many views based on the prior knowledge about the pathways). Method abbreviation: *cwKBMF*, kernelized Bayesian matrix factorization with component-wise MKL; KBMF, kernelized Bayesian matrix factorization; BMTMKL, Bayesian multi-task MKL; KPMF, kernelized probabilistic matrix factorization; MT-LR, multi-task sparse linear regression; Baseline, mean of the training data. P-values show the statistical significance of the improvements of *cwKBMF*'s predictions compared to other methods computed with one-sided paired Wilcoxon Sign-Rank test.




Figure S4: Statistical significance of *in silico* predictions obtained via randomizations test with 10000 random permutations of the drug responses. Spearman correlation = 0.44 found to be significant with  $p = 0.0027$ , than random distribution.